期刊
JOURNAL OF DERMATOLOGICAL TREATMENT
卷 34, 期 1, 页码 -出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/09546634.2023.2284105
关键词
Hidradenitis suppurativa; treatment costs; innovative care concept; ambulatory care
类别
Hidradenitis suppurativa (HS) incurs substantial treatment costs, which increase with disease severity. A structured, multimodal form of care has been found to reduce costs in the treatment of HS compared to standard care.
Background Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease affecting approximately 1% of the population. The patient journey through the German health care system leads to high disease burden and substantial treatment costs. The EsmAiL study showed that an innovative, interprofessional, multimodal care-concept reduces disease activity and burden of HS compared to standard care. This paper examines the costs of treating HS in Germany and compares them with those of the innovative care concept implemented in EsmAiL.Methods EsmAiL was a two-arm, multicenter, prospective randomized controlled trial including 553 adults with HS. The study was registered in the German Clinical Trials Registry (DRKS00022135). The control group (CG) remained in standard care, whereas the intervention group (IG) was referred to specialized so-called 'acne-inversa-centres (AiZ)' where patients were treated with a structured, interdisciplinary approach. The present paper analyses the treatment costs for a subpopulation based on health insurance cost data from the two largest German health insurers. Quality-Adjusted Life Years (QALY) was assessed based on Dermatology Life Quality Index (DLQI).Results Total annual treatment costs per patient were euro3,966.07 in standard care (n = 89) and euro3,974.37 in the innovative care (n = 93). The costs per additional QALY amounted to euro12,698.72 in the IG. Given the conventional and established threshold of euro22,600 to euro33,900 per QALY, the innovative treatment in AiZ proved to be cost-effective.Conclusion Treatment costs of HS are substantial and increase with disease severity. The new form of care is cost-effective and is expected to decrease costs in the long run. A structured, multimodal form of care reduces costs in the treatment of Hidradenitis suppurativa compared to standard care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据